

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION N	D. F	TILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/003,850		11/02/2001	Sreekumar Pillai	J6673(C)	6359
201	7590	06/20/2003			
UNILEV			EXAMINER		
45 RIVER			TRAVERS, RUSSELL S		
EDGEWA	ATER, NJ (07020		ART UNIT	PAPER NUMBER
				1617	
			DATE MAILED: 06/20/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 10/003,850 Applicant(s)

Pillai et al

Examiner

R.S. Travers J.D., Ph.D.

Art Unit **1617**

	The MAILING DATE of this communication appears	on the cover she	et with	the correspondence address			
	for Reply						
THE	IORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.						
mailing	sions of time may be available under the provisions of 37 CFR 1.136 (a). In g date of this communication.						
- If NO p - Failure - Any re	period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply as to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the different term adjustment. See 37 CFR 1.704(b).	and will expire SIX (6) M the application to become	MONTHS fi	from the mailing date of this communication.			
Status							
1) 🗆	Responsive to communication(s) filed on			·			
2a) ∐		ction is non-final.					
3) 🗆	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.						
	ition of Claims						
4) (X I	Claim(s) <u>1-8</u>			is/are pending in the application.			
	4a) Of the above, claim(s)			•			
	Claim(s)						
6) 🗆	Claim(s)	-7+tr		is/are rejected.			
	Claim(s)						
8) 💢	Claims <u>1-8</u>			t to restriction and/or election requirement.			
Application Papers							
9) 🗆	The specification is objected to by the Examiner.						
10)	The drawing(s) filed on is/are	a) 🗆 accepted	or b)Ė	\Box objected to by the Examiner.			
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)	The proposed drawing correction filed on			approved b) \square disapproved by the Examiner.			
	If approved, corrected drawings are required in reply t	to this Office actio					
12)	The oath or declaration is objected to by the Exami	iner.					
	under 35 U.S.C. §§ 119 and 120						
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some* c) None of:							
_	1. Certified copies of the priority documents have been received.						
	2. U Certified copies of the priority documents have been received in Application No.						
	 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. 						
_							
	a) \Box The translation of the foreign language provisional application has been received. 15) \Box Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachme		priority under 30) U.S.C	J. 99 120 and/or 121.			
		41 T Interview Summ	IPTO	1.4191 Pages No./-1			
	tice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary (PTO-413) Paper No(s). 5) Notice of Informal Patent Application (PTO-152)					
		6) Other:					

Art Unit:

Restriction to one of the following inventions is required under 35 U.S.C. § 121:

- I. Claims 1-2 and 5-6, drawn to a stable skin care composition containing retinoid compounds and retinoid boosters.
- II. Claims 3 and 7, drawn to a method for conditioning skin by applying a stable skin care composition containing retinoid compounds and retinoid boosters.
 - III. Claims 4 and 8, drawn to a method of mimicking the effects of retinoic acid.

Claims contained in Groups I-III are directed to patentably unrelated compositions of matter and therapeutic methods employing a plurality of patentably distinct compound species. Applicant is required under 35 U.S.C. § 121 to elect a single disclosed invention, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.

The above delineated inventions differ as compositions of matter and unrelated therapeutic methods; and are independent and patentably distinct each from the other. The grouped inventions patentably distinct, a reference which would anticipate, or make obvious, the inventions of groups I-III would not necessarily obviate or anticipate

Application/Control Number: 10/003,850

Page 3

Art Unit:

the inventions in the other group. The searches are not co-inclusive as indicated by the diverse nature of the subject matter, thus, would represent an undue burden on Examiner. One skilled in the art would readily practice the invention of one of the above groups with out infringing and or practicing the invention of another group. The subject matter is unique and has acquired a separate status in the art and is fully capable of supporting separate patents. For the foregoing reasons restriction is proper for examination purposes.

Applicant is reminded that upon the cancellation of the claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. 1.48 (b) if one or more of the currently named inventors is no longer an inventor if at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently filed petition under 37 C.F.R. 1.48 (b) and by the fee required under 37 C.F.R. 1.17 (h).

Any inquiry concerning this communication should be directed to Russell Travers at telephone number (703) 308-4603.

Russell Travers
Primary Examiner
Art Unit 1617